Literature DB >> 3333410

Whole-body hyperthermia. Rationale and potential use for cancer treatment.

R L Page1, D E Thrall, M W Dewhirst, R E Meyer.   

Abstract

Whole-body hyperthermia is the controlled elevation of systemic temperature for therapeutic purposes. Historically, this treatment has been used for symptomatic control of many diseases. Recently, the potential therapeutic benefit of whole-body hyperthermia in the management of neoplastic disease has been investigated vigorously. The rationale for improved tumor control is based on heat-induced enhancement of the antineoplastic effects of radiation and chemotherapy. Although the complex biologic interaction of heat and radiation has been studied for many years, chemotherapy combined with hyperthermia has been studied less thoroughly. Despite a lack of adequate long-term laboratory and clinical investigation, use of whole-body hyperthermia with chemotherapy and radiotherapy is a logical and potentially powerful therapeutic strategy for neoplasia. Relevant issues regarding the application of whole-body hyperthermia with more traditional modes of therapy are being studied in preliminary clinical trials involving dogs and humans. Identification of optimal timing and sequencing of adjunctive therapy, proper cytotoxic drug application, methods to further minimize toxicity, and heat-sensitive tumor types will lead to expanded clinical use of whole-body hyperthermia. The historical development, clinical rationale, and application of whole-body hyperthermia for the control of disseminated or refractory neoplasia in humans and dogs is reviewed.

Entities:  

Mesh:

Year:  1987        PMID: 3333410     DOI: 10.1111/j.1939-1676.1987.tb01998.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  5 in total

1.  Hematological effects of radiant heat-induced whole body hyperthermia on dogs.

Authors:  J P Woods; C L Schmitt-Tiggelaar; F d'Oleire; R C Rosenthal; H I Robins
Journal:  Can J Vet Res       Date:  1996-01       Impact factor: 1.310

2.  Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.

Authors:  A E Korst; E Boven; M L van der Sterre; A M Fichtinger-Schepman; W J van der Vijgh
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 3.  The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway.

Authors:  Ira Gordon; Melissa Paoloni; Christina Mazcko; Chand Khanna
Journal:  PLoS Med       Date:  2009-10-13       Impact factor: 11.069

4.  HSPB1 deficiency sensitizes melanoma cells to hyperthermia induced cell death.

Authors:  He-Xiao Wang; Yang Yang; Hao Guo; Dian-Dong Hou; Song Zheng; Yu-Xiao Hong; Yun-Fei Cai; Wei Huo; Rui-Qun Qi; Li Zhang; Hong-Duo Chen; Xing-Hua Gao
Journal:  Oncotarget       Date:  2016-10-11

Review 5.  Magnetic Hyperthermia and Radiation Therapy: Radiobiological Principles and Current Practice .

Authors:  Spiridon V Spirou; Martina Basini; Alessandro Lascialfari; Claudio Sangregorio; Claudia Innocenti
Journal:  Nanomaterials (Basel)       Date:  2018-06-03       Impact factor: 5.076

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.